Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 20 to 60 years~* Presence of mono-infection of P. falciparum or P. vivax~* Weight between 40 kg to 90 kg~Exclusion Criteria:~* Patients with signs and symptoms of severe/complicated malaria~* Mixed Plasmodium infection~* Presence of other serious or chronic clinical condition requiring hospitalization.~* Severe malnutrition~* Significant chronic medical conditions which in the opinion of the investigator preclude enrollment into the study~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 10 subjects with Plasmodium vivax malaria will receive 30 mg KAE609 once a day for three days
- Cohort 2 (Type: EXPERIMENTAL): 10 subjects with Plasmodium falciparum malaria will receive 30 mg KAE609 once a day for three days

Based on this trial design, predict the completion outcome and termination type (if applicable).